Galmed updates business and clinical development strategy to better leverage aramchol's anti-fibrotic effects

Recent data reinforce the anti-fibrotic activity of aramchol previously observed in a wide range of pre-clinical models, in addition to the known effects in liver fibrosis the open-label part of the armor study met its objectives demonstrating consistent anti-fibrotic effects at 48 weeks in nash patients and will be discontinued cost reduction will allow rapid transition to anti-fibrotic indications with high unmet need and faster development pathways company evaluating strategic alternatives to enhance shareholder value tel aviv, israel , may 17, 2022 /prnewswire/ -- galmed pharmaceuticals ltd. (nasdaq: glmd) ("galmed" or the "company"), a clinical-stage biopharmaceutical company for liver, metabolic, fibrosis and inflammatory diseases announced today the company's clinical development strategy will expand into new anti-fibrotic indications to maximize the potential of its lead compound, aramchol while at the same time discontinuing the open label part of the armor study having reached its objectives.
GLMD Ratings Summary
GLMD Quant Ranking